Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.
about
Update on the treatment of patients with non-genotype 1 hepatitis C virus infectionGenetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactionsImpact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.Hepatitis C in Argentina: epidemiology and treatment.Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphismsHepatitis C virus infection in the human immunodeficiency virus infected patient.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C.Cost-effectiveness of IL28Β genotype-guided protease inhibitor triple therapy versus standard of care treatment in patients with hepatitis C genotypes 2 or 3 infection.Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis.The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirinImpact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection.The impact of IL-6 and IL-28B gene polymorphisms on treatment outcome of chronic hepatitis C infection among intravenous drug users in Croatia.Individualization of chronic hepatitis C treatment according to the host characteristics.What's new in HCV genotype 2 treatment.Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.Introduction to the genetics and biology of interleukin-28B.Genetics of IL28B and HCV--response to infection and treatment.IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.The role of pharmacogenetics in the treatment of chronic hepatitis C infection.Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.Dynamic tailoring of treatment durations improves efficiency of hepatitis C treatment with pegylated interferon and ribavirin.HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism.Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C.IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.Natural history of hepatitis C in thalassemia major: a long-term prospective study.Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy.Interleukin-28B polymorphism in hepatitis C and liver transplantation.Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives.
P2860
Q27000806-8E544E5A-0699-4994-80E4-E2F112FD796AQ27014831-0D5E211B-929C-4F7B-A844-0C70E2CC6FEBQ28732828-4EDDD73C-4F6D-42F5-BAE5-2ADEC4EBE828Q33413296-A04FB5F5-89EB-4B48-8A4A-998FE237DE20Q33706886-B16399A8-A4D1-4CE0-8BB1-2B0EE0BEC25CQ34007851-69B97753-539E-446F-BF5B-033C1CA612BCQ34036824-4DABC8F1-F796-447B-B5AB-F173D399881AQ34168504-2DF73A3A-F411-4341-90B6-5BA4552CB4A8Q34375569-BB1D1EA6-5379-4697-A07A-1B4EEAFFDE80Q34429833-7E5CD87C-4716-4F99-8C35-A4B2C62913AFQ34485088-5C55226C-81F4-4C18-9011-3C2B2C2E1413Q34539324-F1BB1597-7A6D-479F-98CA-5FBC7F60C135Q34765761-4FC0CD77-20F4-4E5D-B5D9-44058965180CQ35122925-F090BEE3-932E-40A1-9B12-0654BA889D0FQ35812034-8BF05FB2-0612-4D08-986E-B4BA7FBF03CBQ37308845-01CF6739-621F-4090-905D-9B84EB7F3A13Q37383288-F1E00838-0CCE-4ADE-B2ED-C6A3E85F3C34Q37654502-777760CA-DAAB-4EA1-82AB-A14434524749Q37972773-A00E14FE-D901-4F8B-B8DD-24D4105FCE79Q37972774-2AE0B233-DBDB-46ED-8B14-C9C3B8D26305Q38003354-CD7732B0-79AD-4BC5-BCAD-471D6D877E0DQ38013941-19027D6B-6D60-4EC5-928D-625AAB9810B8Q38053543-0DA2AE10-6332-440A-A798-7DA2CC49313BQ38151586-F86989CB-D2A4-46CF-8CB1-3F3672EE4A90Q38174868-80CD09AE-9D5F-425A-967E-15162AB2DCA0Q42208106-1CDD0CCC-328C-4108-903B-DA17F3390D28Q42257750-E5D8864C-3F57-4C92-A1CC-EF9FDEFA0F67Q42271105-9A7E355E-4C02-4E5D-80C3-73B4AE281263Q42276236-1C7C0B0A-AC70-4E24-8D83-317035774E24Q42284820-39768DA5-215B-450E-BC0E-C80FCE93EB84Q42913315-D90F57B1-E516-4714-9CE3-2235D1754B96Q42981780-A016058F-A2FA-4CC5-B900-2982926BD3A0Q42989273-9BEB6086-E78C-4246-A9E9-C237E561A21FQ42991482-B8D70299-3C43-4EAD-8C8D-32952EEAE2C5Q43445309-B5CC0AFD-8242-451B-8523-0A17CC81BEDEQ50555301-1BEE34D8-323A-4048-8B1F-318618A9FEEC
P2860
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@en
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@nl
type
label
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@en
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@nl
prefLabel
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@en
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@nl
P2093
P50
P356
P1476
Interleukin 28B gene variation ...... s 2 or 3 of hepatitis C virus.
@en
P2093
Court Pedersen
Gunnar Norkrans
Johan Westin
Kristine Mørch
Mads Rauning Buhl
Magnus Lindh
Nina Langeland
P304
P356
10.1093/INFDIS/JIR193
P407
P577
2011-06-01T00:00:00Z